e-therapeutics plc (LON:ETX – Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 9.48 ($0.12) and traded as low as GBX 9 ($0.11). e-therapeutics shares last traded at GBX 9 ($0.11), with a volume of 2,518,125 shares changing hands.
e-therapeutics Stock Performance
The company has a market cap of £52.59 million, a price-to-earnings ratio of -450.00 and a beta of 0.46. The company has a fifty day moving average of GBX 9 and a two-hundred day moving average of GBX 9.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 20.13 and a current ratio of 22.20.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
See Also
- Five stocks we like better than e-therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- What is a Special Dividend?
- Top-Performing Non-Leveraged ETFs This Year
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
